Abstract:Viruses have evolved to traverse cellular barriers and travel to the nucleus by mechanisms that involve active transport through the cytoplasm and viral quirks to resist cellular restriction factors and innate immune responses. Virus-derived vector systems exploit the capacity of viruses to ferry genetic information into cells, and now - more than three decades after the discovery of HIV - lentiviral vectors based on HIV-1 have become instrumental in biomedical research and gene therapies that require genomic insertion of transgenes. By now, the efficacy of lentiviral gene delivery to stem cells, cells of the immune system including T cells, hepatic cells, and many other therapeutically relevant cell types is well established. Along with nucleic acids, HIV-1 virions carry the enzymatic tools that are essential for early steps of infection. Such capacity to package enzymes, even proteins of nonviral origin, has unveiled new ways of exploiting cellular intrusion of HIV-1. Based on early findings demonstrating the packaging of heterologous proteins into virus particles as part of the Gag and GagPol polypeptides, we have established lentiviral protein transduction for delivery of DNA transposases and designer nucleases. This strategy for delivering genome-engineering proteins facilitates high enzymatic activity within a short time frame and may potentially improve the safety of genome editing. Exploiting the full potential of lentiviral vectors, incorporation of foreign protein can be combined with the delivery of DNA transposons or a donor sequence for homology-directed repair in so-called 'all-in-one' lentiviral vectors. Here, we briefly describe intracellular restrictions that may affect lentiviral gene and protein delivery and review the current status of lentiviral particles as carriers of tool kits for genome engineering.

Efficient lentiviral transduction of liver requires cell cycling in vivo

Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

Analysis of hepatic lentiviral vector transduction; implications for preclinical studies and clinical gene therapy protocols

Analysis of hepatic lentiviral vector transduction; implications on preclinical studies and clinical gene therapy protocols.

Autoregulatory lentiviral vectors allow multiple cycles of doxycycline-inducible gene expression in human hematopoietic cells in vivo

Optimization of a lentivirus-mediated gene therapy targeting HIV-1 RNA to eliminate HIV-1-infected cells

Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy

Progression and Application of HIV-1-derived Lentivectors

Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy.

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Transactivator and Structurally Optimized Inducible Lentiviral Vectors.

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization

Lentiviral Delivery of Proteins for Genome Engineering

Efficient lentiviral transduction of different human and mouse cells

Lentiviral Vector Transduction of Hematopoietic Stem Cells That Mediate Long‐Term Reconstitution of Lethally Irradiated Mice

A Self-Deletion Lentiviral Vector to Reduce the Risk of Replication-Competent Virus Formation

Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition

Integrase-deficient lentivirus: opportunities and challenges for human gene therapy.

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors